Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 239 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: aripiprazole Clear all
Completed Not applicable Interventional Results available

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

NCT00468130
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

NCT00222833
View directory record Official record
Conditions
Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions
Aripiprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Aripiprazole as Augmentation for TRD

NCT00174876
View directory record Official record
Conditions
Depression
Interventions
Drug Abilify
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

NCT01129882
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
52
States / cities
Bellevue, California • Garden Grove, California • Glendale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 2, 2026, 5:23 AM EDT
Completed No phase listed Observational

Long-term Antipsychotic Pediatric Safety Trial

NCT03522168
View directory record Official record
Conditions
Weight, Body
Interventions
Risperidone, Aripiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
37
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

NCT00363337
View directory record Official record
Conditions
Bipolar Depression
Interventions
aripiprazole
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Results available

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

NCT00288353
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
aripiprazole (Abilify), ziprasidone (Geodon)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

NCT00592683
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
Aripiprazole, fish oil, Placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 2, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554
View directory record Official record
Conditions
Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions
Lumateperone 42 mg, Risperidone 2 mg
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 2, 2026, 5:23 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCT01469039
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Aripiprazole in Children With Autism: A Pilot Study

NCT00208533
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Risperdal Consta for Bipolar Disorder

NCT00177164
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Injectable Risperidone (Consta) or oral antipsychotic
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

C-Cog in Early Course Schizophrenia Study

NCT05662306
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Computerized cognitive and functional skills training
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Aripiprazole to Reduce Cocaine Relapse

NCT00276874
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

NCT00036127
View directory record Official record
Conditions
Schizophrenia
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
16
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 2, 2026, 5:23 AM EDT